Jeffrey O'brien
About Jeffrey O'brien
Jeffrey O'Brien is a Scientist specializing in Nanotechnology at Bristol Myers Squibb in San Diego, CA, with a background in Chemistry and Biochemistry.
Company
Jeffrey O'Brien is currently working at Bristol Myers Squibb as a Scientist specializing in Nanotechnology. He is based in San Diego, CA, United States. His role involves developing innovative nanotechnology-based drug products and therapeutic solutions.
Title
Jeffrey O'Brien holds the title of Scientist in Nanotechnology. His primary responsibilities are focused on the development and application of nanotechnology in drug product development, particularly for therapeutic solutions.
Education and Expertise
Jeffrey O'Brien studied at the University of California, Irvine, where he earned a Doctor of Philosophy (PhD) in Chemistry from 2013 to 2018. Prior to that, he obtained his Bachelor's degree in Biochemistry from the University of San Diego, completing his studies from 2008 to 2012. His academic background has equipped him with a strong foundation in chemistry and nanotechnology, which he applies in his current research and development work.
Background
Jeffrey O'Brien has extensive research experience in the field of nanotechnology. He worked at Bristol Myers Squibb from 2019 to 2021 as a Scientist in Chemistry and Nanotechnology Drug Product Development. Before that, he was a Postdoctoral Research Fellow at Johns Hopkins Institute for NanoBioTechnology for 11 months in 2019. His earlier roles include Graduate Student Researcher at UC Irvine from 2013 to 2018, Undergraduate Researcher at the University of San Diego from 2011 to 2013, and Laboratory Technician at CalciMedica Inc from 2010 to 2012.
Achievements
Jeffrey O'Brien has published multiple research papers on nanotechnology applications in healthcare. He presented his findings on nanoparticle drug delivery systems at the 2022 Nanomedicine Conference. Additionally, he developed a novel nanoparticle formulation that significantly improves drug solubility. His collaborative efforts with interdisciplinary teams have advanced nanotechnology-based therapeutic solutions. He also received a grant from the National Institutes of Health (NIH) for his research on targeted cancer therapies using nanotechnology.